In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

HTA in a Public Crisis: Communication Challenges


Moderator: Francois Houyez, Patient Advocate, European Organisation for Rare Diseases (EURORDIS), Paris, France
Panelists: Saskia Knies, PhD, Health Care Institute, Diemen, NH, Netherlands; Dalia Dawoud, PhD, National Institute for Health and Care Excellence, London, LON, UK; Bertalan Németh, PhD, ISPOR Hungary Chapter, Senior Health Economist, ISPOR CEE Consortium Executive Committee and Syreon Research Institute, Budapest, Hungary

Presentation Documents

ISSUE: As a major public health crisis, the COVID-19 pandemic challenges healthcare systems and decision-makers, as important decisions relating to new health technologies have to be made under considerable uncertainty and pressure. At the same time, researchers are still themselves learning about the emerging condition. They find themselves in a “ doing while learning” position, where only partial information is available and initial positive results may be followed by negative ones, or early negative results are followed by other, more positive, results. Knowledge is constantly challenged, uncertainties are high and while seemingly a large amount of literature is available, its validity is often questionable . Despite all of these limitations, there is a significant pressure on HTA agencies are requested to provide rapid opinions on a range of questions: which populations could benefit the most from different interventions? Whom to vaccinate first? What role for monoclonal antibodies or antiviral treatments for people at different disease stages (with or without oxygen, hospitalized or not, pre-exposure or post-exposure prophylaxis etc.). What’s the right way to inform the public about the rationale of this work and consequent decisions?

OVERVIEW: The moderator will briefly introduce the issue (4 mins) and the panel will then debate the concerns of challenging HTA communication and on perspective on the questions set out above. Panelists will each speak for 10 minutes, providing their perspectives on the issues as well as the key considerations. 20 minutes will be reserved for audience discussion.

The panel will be of interest to those working in HTA, healthcare professionals and patient organisations




Health Technology Assessment